research:large-scale_modeling_of_patients_with_thyroid_conditions
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
research:large-scale_modeling_of_patients_with_thyroid_conditions [2017/04/16 09:00] burculantonija |
research:large-scale_modeling_of_patients_with_thyroid_conditions [2017/04/21 19:13] burculantonija |
||
|---|---|---|---|
| Line 3: | Line 3: | ||
| <WRAP box justify round> | <WRAP box justify round> | ||
| - | **Objective:** //Characterisation of non-cancerous thyroid disorder population and identification and characterisation of sources of variation within treatment pathways for thyroid conditions// | + | **Objective:** //Characterisation of non-cancerous thyroid disorder population and identification and characterisation of sources of variation within treatment pathways for thyroid conditions.// |
| **Rationale:** //There are an estimated 200 million people worldwide who suffer from some form of thyroid disease according to the Thyroid Foundation of Canada. Women are 5-8 times more likely to develop it than men. 5-10 % of pregnancies end up with postpartum thyroiditis. Over 12 % of the US population has some type of a thyroid condition. As a result, synthetic thyroid hormone is the top prescribed medication in USA with more than 20 million prescriptions per month. Patients who suffer from the symptoms of the disease often spend years un- or misdiagnosed. Depending on the type of the condition symptoms include, among others, anxiety, weight gain or loss, depression and brain fog. Patients can suffer from symptoms of the disease even though their thyroid stimulating hormone (TSH) values are within the reference ranges. Currently, the treatment for any type of a thyroid condition includes the process of testing different drug combinations and doses for a period of time until the optimal one is found. | **Rationale:** //There are an estimated 200 million people worldwide who suffer from some form of thyroid disease according to the Thyroid Foundation of Canada. Women are 5-8 times more likely to develop it than men. 5-10 % of pregnancies end up with postpartum thyroiditis. Over 12 % of the US population has some type of a thyroid condition. As a result, synthetic thyroid hormone is the top prescribed medication in USA with more than 20 million prescriptions per month. Patients who suffer from the symptoms of the disease often spend years un- or misdiagnosed. Depending on the type of the condition symptoms include, among others, anxiety, weight gain or loss, depression and brain fog. Patients can suffer from symptoms of the disease even though their thyroid stimulating hormone (TSH) values are within the reference ranges. Currently, the treatment for any type of a thyroid condition includes the process of testing different drug combinations and doses for a period of time until the optimal one is found. | ||
| Line 9: | Line 9: | ||
| // | // | ||
| - | **Project Lead(s):** //Antonija Burcul, Frank DeFalco, Jill Hardin// | + | **Project Lead(s):** //Antonija Burcul, Frank DeFalco, Jill Hardin.// |
| **Coordinating Institution(s):** //// | **Coordinating Institution(s):** //// | ||
| Line 16: | Line 16: | ||
| Dr. med. Ivette Engel-Bicik, Switzerland, | Dr. med. Ivette Engel-Bicik, Switzerland, | ||
| Dr. med. Maria Tulpan, USA, | Dr. med. Maria Tulpan, USA, | ||
| - | Dr. med. Kent Holfort, USA | + | Dr. med. Kent Holfort, USA. |
| // | // | ||
| - | **Full Protocol:** //[[https://github.com/OHDSI/StudyProtocolSandbox/raw/master/HypertensionCombination/documents/HTN_combi_protocol_ver0.3(17.1.2).docx|Word doc for the protocol]] // | + | **Full Protocol:** // |
| + | [[https://github.com/OHDSI/StudyProtocolSandbox/blob/master/LargeScaleModelingThyroid/documents/OHSDI_thyroidproposal_final.docx|Large Scale Modeling of Thyroid Patients Full Protocol]]// | ||
| **Initial Proposal Date:** April 2017 | **Initial Proposal Date:** April 2017 | ||
| Line 25: | Line 26: | ||
| **Launch Date:** 16 April 2017 // // | **Launch Date:** 16 April 2017 // // | ||
| - | **Study Closure Date: // //** | + | **Study Closure Date: //Pending//** |
| - | **Results Submission:** //<method of submission, [[mailto:applegna@gmail.com|Email]]>// | + | **Results Submission:** //// |
| </WRAP> | </WRAP> | ||
| ===== Requirements ===== | ===== Requirements ===== | ||
| - | **CDM:** //V5 only// | + | **CDM:** //V4 or V5// |
| - | **Table Accessed:** //person, drug_exposure, drug_era, death, condition_occurrence, measurement, procedure_occurrence, visit_occurrence// | + | **Table Accessed:** //// |
| **Database Dialects:** SQL Server, Postgres, Oracle | **Database Dialects:** SQL Server, Postgres, Oracle | ||
| Line 41: | Line 42: | ||
| ===== Code ===== | ===== Code ===== | ||
| - | [[https://github.com/OHDSI/StudyProtocolSandbox/tree/master/HypertensionCombination]] | ||
| ===== Discussion ===== | ===== Discussion ===== | ||
| - | //Post a thread letting everyone know about this new proposed study at [[http://forums.ohdsi.org/c/researchers]]// | + | //Discussion thread available [[http://forums.ohdsi.org/t/ohdsi-study-large-scale-modeling-of-patients-with-thyroid-conditions/2613|here]].// |
| ===== Datasets Run ===== | ===== Datasets Run ===== | ||
| - | * <list your own datasets or leave blank> | ||
| ~~NOTOC~~ | ~~NOTOC~~ | ||
research/large-scale_modeling_of_patients_with_thyroid_conditions.txt · Last modified: 2017/04/21 19:13 by burculantonija
Page Tools
